Triiodothyroacetic acid in health and disease
- S Groeneweg, Internal Medicine, Erasmus Medical Center, Rotterdam, 3015 CN, Netherlands
- R Peeters, Internal Medicine, Erasmus MC, Rotterdam, 3000DR, Netherlands
- T Visser, Internal Medicine, Erasmus MC, Rotterdam, 3015 GE, Netherlands
- W Visser, Internal Medicine, Erasmus University Medical Center, Rotterdam, Netherlands
- Correspondence: W Edward Visser, Email: w.e.visser{at}erasmusmc.nl
Abstract
Thyroid hormone (TH) is crucial for development and metabolism of many tissues. The physiological relevance and therapeutic potential of TH analogs have gained attention in the field for many years. In particular, the relevance and use of 3,3',5- triiodothyroacetic acid (Triac, TA3) has been explored over the last decades. Although TA3 closely resembles the bioactive hormone T3, differences in transmembrane transport and receptor isoform-specific transcriptional activation potency exist. For these reasons, the application of TA3 as a treatment for resistance to TH (RTH) syndromes, especially MCT8 deficiency, is topic of ongoing research. This review is a summary of all currently available literature about the formation, metabolism, action and therapeutic applications of TA3.
- Received 24 February 2017
- Received in final form 26 May 2017
- Accepted 30 May 2017
- Accepted Preprint first posted online on 1 June 2017
